Since the levels of catalase were not changed in the diabetic heart with or without treatment, it is likely that the modification of oxidative stress biomarkers by diabetes, as well as due to insulin or sarpogrelate treatment, is site-specific in the oxidative stress pathway. This evidence concerns the gene CAT and diabetes mellitus.